163 related articles for article (PubMed ID: 16435211)
1. Mucopolysaccharidosis I under enzyme replacement therapy with laronidase--a mortality case with autopsy report.
Lin HY; Lin SP; Chuang CK; Chen MR; Chen BF; Wraith JE
J Inherit Metab Dis; 2005; 28(6):1146-8. PubMed ID: 16435211
[TBL] [Abstract][Full Text] [Related]
2. Laronidase.
BioDrugs; 2002; 16(4):316-8. PubMed ID: 12196045
[TBL] [Abstract][Full Text] [Related]
3. Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome.
Thomas JA; Jacobs S; Kierstein J; Van Hove J
J Inherit Metab Dis; 2006 Dec; 29(6):762. PubMed ID: 17089217
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
Wraith JE; Clarke LA; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Swiedler SJ; Kakkis ED; Braakman T; Chadbourne E; Walton-Bowen K; Cox GF
J Pediatr; 2004 May; 144(5):581-8. PubMed ID: 15126990
[TBL] [Abstract][Full Text] [Related]
5. Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I.
Anbu AT; Mercer J; Wraith JE
J Inherit Metab Dis; 2006 Feb; 29(1):230-1. PubMed ID: 16601901
[TBL] [Abstract][Full Text] [Related]
6. Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series.
Horovitz DD; Acosta AX; Giugliani R; Hlavatá A; Hlavatá K; Tchan MC; Lopes Barth A; Cardoso L; Embiruçu de Araújo Leão EK; Esposito AC; Kyosen SO; De Souza CF; Martins AM
Orphanet J Rare Dis; 2016 Apr; 11(1):51. PubMed ID: 27129473
[TBL] [Abstract][Full Text] [Related]
7. Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase).
Tylki-Szymanska A; Rozdzynska A; Jurecka A; Marucha J; Czartoryska B
Mol Genet Metab; 2010 Jan; 99(1):10-7. PubMed ID: 19783188
[TBL] [Abstract][Full Text] [Related]
8. Postmortem studies on a patient with mucopolysaccharidosis type I: histopathological findings after one year of enzyme replacement therapy.
Yano S; Moseley K; Pavlova Z
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S53-7. PubMed ID: 19308670
[TBL] [Abstract][Full Text] [Related]
9. Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy.
Langereis EJ; van Vlies N; Church HJ; Geskus RB; Hollak CE; Jones SA; Kulik W; van Lenthe H; Mercer J; Schreider L; Tylee KL; Wagemans T; Wijburg FA; Bigger BW
Mol Genet Metab; 2015 Feb; 114(2):129-37. PubMed ID: 25467058
[TBL] [Abstract][Full Text] [Related]
10. Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease.
Hsu YH; Liu RS; Lin WL; Yuh YS; Lin SP; Wong TT
Orphanet J Rare Dis; 2017 Jun; 12(1):109. PubMed ID: 28595620
[TBL] [Abstract][Full Text] [Related]
11. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I.
Wraith JE
Expert Opin Pharmacother; 2005 Mar; 6(3):489-506. PubMed ID: 15794739
[TBL] [Abstract][Full Text] [Related]
12. Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies.
Xue Y; Richards SM; Mahmood A; Cox GF
Mol Genet Metab; 2016 Apr; 117(4):419-26. PubMed ID: 26920513
[TBL] [Abstract][Full Text] [Related]
13. Laronidase opens door to treat other rare disorders.
Morrow T
Manag Care; 2004 Jun; 13(6):52-3. PubMed ID: 15259445
[No Abstract] [Full Text] [Related]
14. Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human alpha-L-iduronidase (laronidase, Aldurazyme).
Kloska A; Bohdanowicz J; Konopa G; Tylki-Szymńska A; Jakóbkiewicz-Banecka J; Czartoryska B; Liberek A; Wegrzyn A; Wegrzyn G
Am J Med Genet A; 2005 Dec; 139(3):199-203. PubMed ID: 16283671
[TBL] [Abstract][Full Text] [Related]
15. Alpha-L-iduronidase (laronidase; aldurazyme).
Med Lett Drugs Ther; 2003 Oct; 45(1168):88. PubMed ID: 14576624
[No Abstract] [Full Text] [Related]
16. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.
Sifuentes M; Doroshow R; Hoft R; Mason G; Walot I; Diament M; Okazaki S; Huff K; Cox GF; Swiedler SJ; Kakkis ED
Mol Genet Metab; 2007 Feb; 90(2):171-80. PubMed ID: 17011223
[TBL] [Abstract][Full Text] [Related]
17. Decreased corneal opacity and improved vision in a patient with mucopolysaccharidosis I (Hurler-Scheie) treated with enzyme replacement therapy (laronidase, Aldurazyme).
Cáceres-Marzal C; García-Reymundo M; Solana J; de Arévalo B; Vaquerizo J; Galán E
Am J Med Genet A; 2008 Jul; 146A(13):1768-70. PubMed ID: 18546328
[No Abstract] [Full Text] [Related]
18. Impact of 144 weeks of laronidase therapy on body functions, endurance and general well-being in a Hurler-Scheie patient.
Soutar RL; Mercer J; Wraith JE
J Inherit Metab Dis; 2006 Aug; 29(4):590. PubMed ID: 16830264
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis.
Pérez-López J; Morales-Conejo M; López-Rodríguez M; Hermida-Ameijeiras Á; Moltó-Abad M
Mol Genet Metab; 2017 Jun; 121(2):138-149. PubMed ID: 28410878
[TBL] [Abstract][Full Text] [Related]
20. [Laronidase for treating post-surgical respiratory failure in a patient with type I mucopolysaccharidosis].
Vélez-Díaz-Pallarés M; Sánchez Cuervo M; Martínez-Pardo Casanova M; Bermejo Vicedo T
Farm Hosp; 2012; 36(1):55-6. PubMed ID: 21641259
[No Abstract] [Full Text] [Related]
[Next] [New Search]
